AdaptiM3D brings together decades of pharmaceutical manufacturing and drug development experience, with a team that has worked across both industrial scale-up and clinical delivery. This depth of insight underpins the development of AdaptiM3D’s approach, shaped by a clear understanding of where traditional manufacturing creates delays and complexity.

AdaptiM3D’s filament-free 3D printing microfactory removes the constraints of traditional and filament-based approaches, enabling direct manufacture of oral solid dosage forms in a single step. This streamlined process expands formulation flexibility and allows precise control of drug release profiles through structure and polymer selection.

Traditional tablet manufacturing has changed little in over 200 years, relying on multi-step processes that can take weeks to complete. AdaptiM3D offers an alternative approach, using a single-step 3D printing process to produce oral solid dosage forms in hours, enabling greater flexibility for clinical development.

AdaptiM3D™ focuses on improving how clinical trial medicines are manufactured and supplied — enabling greater flexibility, speed and dose adjustment where traditional processes fall short.